ArticleFrontiers in oncology2026
Establishment and clinical performance evaluation of the thyroglobulin colloidal gold immunochromatographic assay.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lymph node metastasis increases recurrence risk in differentiated thyroid carcinoma (DTC). To address limitations of conventional detection, this study developed a novel quantitative diagnostic protocol to enhance preoperative assessment accuracy and guide optimal surgical management. Methods: A total of 185 serum samples and 120 lymph node samples from patients scheduled for thyroid lateral neck lymph node resection or biopsy at the Head and Neck Surgery of Shaanxi Provincial Cancer Hospital between July 2023 and December 2023 were detected through the colloidal gold immunochromatographic assay (CGICA) and traditional Roche electrochemiluminescence immunoassay (ECLIA) methods, respectively. The paraffin pathology results served as the gold standard. Results: The CGICA method demonstrated comparable performance to the Roche ECLIA method in serum sample detection, as evidenced by excellent correlation in regression analysis (r=0.996) and Bland-Altman agreement analysis. Notably, when applied to lymph node specimens, the CGICA method with a 22.05 μg/L cutoff value exhibited greater sensitivity than the Roche method with a 233.25 μg/L cutoff value (90% Conclusions: The current study demonstrates the potential of the CGICA method for thyroglobulin detection, which contributes to the rapid detection of cervical lymph node metastases in thyroid cancer patients (clinical trial registry number: ChiCTR2200063561).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.